Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 3

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women

Authors Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias

Published 12 September 2008 Volume 2008:3(3) Pages 445—451

DOI http://dx.doi.org/10.2147/CIA.S2046

Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias

2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Greece

Abstract: Zoledronic acid is a nitrogen-containing, third-generation bisphosphonate that has recently been approved for the treatment of postmenopausal osteoporosis as an annual intravenous infusion. Zoledronic acid is an antiresorptive agent which has a high affinity for mineralized bone and especially for sites of high bone turnover. Zoledronic acid is excreted by the kidney without further metabolism. Zoledronic acid administered as a 5 mg intravenous infusion annually increases bone mineral density in the lumbar spine and femoral neck by 6.7% and 5.1% respectively and reduces the incidence of new vertebral and hip fractures by 70% and 41% respectively in postmenopausal women with osteoporosis. Most common side effects are post-dose fever, flu-like symptoms, myalgia, arthralgia, and headache which usually occur in the first 3 days after infusion and are self-limited. Rare adverse effects include renal dysfunction, hypocalcemia, atrial fibrillation, and osteonecrosis of the jaw.

Keywords: zoledronic acid, postmenopausal osteoporosis, bisphosphonate

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Age-related reduction of cerebral ischemic preconditioning: myth or reality?

Della-Morte D, Caciatore F, Salsano E, Pirozzi G, Del Genio MT, D'Antonio I, Gargiulo G, Palmirotta R, Guadagni F, Rundek T, Abete P

Clinical Interventions in Aging 2013, 8:1055-1061

Published Date: 8 August 2013

Metabolic biomarkers for predicting cardiovascular disease

Montgomery JE, Brown JR

Vascular Health and Risk Management 2013, 9:37-45

Published Date: 29 January 2013

Diagnostic accuracy of dual-source CT angiography and coronary risk stratification

Xia Yang, Lu-yue Gai, Ping Li, et al

Vascular Health and Risk Management 2010, 6:935-941

Published Date: 14 October 2010

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer

Rajni Sethi, Nicholas Sanfilippo

Clinical Interventions in Aging 2009, 4:259-267

Published Date: 5 June 2009

The impact of SHS exposure on health status and exacerbations among patients with COPD

Mark D Eisner, Carlos Iribarren, Edward H Yelin, Stephen Sidney, et al.

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:169-176

Published Date: 6 May 2009

Hyaluronic acid gel (Juvéderm™) preparations in the treatment of facial wrinkles and folds

Inja Bogdan Allemann, Leslie Baumann

Clinical Interventions in Aging 2008, 3:629-634

Published Date: 5 December 2008

Management of psychosis in patients with Alzheimer’s disease: focus on aripiprazole

Subramanian Madhusoodanan, Payal Shah

Clinical Interventions in Aging 2008, 3:491-501

Published Date: 12 September 2008

Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily

Claus G Roehrborn, Raymond C Rosen

Clinical Interventions in Aging 2008, 3:511-524

Published Date: 12 September 2008

Predictors of adherence to physical activity in the Lifestyle Interventions and Independence for Elders pilot study (LIFE-P)

W Jack Rejeski, Michael E Miller, Abby C King, Stephanie A Studenski, Jeffrey A Katula, et al For the LIFE Investigators (2006)

Clinical Interventions in Aging 2007, 2:485-494

Published Date: 15 October 2007